A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
SARS-CoV-2 Infection
Interventions
DRUG

BTL-TML-COVID

"Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."

DRUG

Placebo

"Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime.~Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment.~Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime.~Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day."

Trial Locations (1)

84020

Intermountain Clinical Reserach, Draper

All Listed Sponsors
collaborator

Norwich Clinical Research Associates Ltd.

OTHER

collaborator

Curavit Clinical Research

UNKNOWN

lead

Beech Tree Labs, Inc.

INDUSTRY